Novocure (NVCR): FDA Approves Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| (NASDAQ: NVCR) | Delayed: 15.59 -0.12 (0.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.71 | 52 Week High | $28.95 | |||
| Open | $15.60 | 52 Week Low | $5.95 | |||
| Day High | $16.09 | P/E | N/A | |||
| Day Low | $15.43 | EPS | $0.00 | |||
| Volume | 2,599,223 | |||||
